Andreana N. Holowatyj, PhD, MS, Talks AACR and the Value of the Annual Meeting 2021

Video

Holowatyj detailed the benefits of a conference like that of the American Association for Cancer Research Annual Meeting 2021, which presents opportunities for thought leaders to come together.

Andreana N. Holowatyj, PhD, MS, of the Vanderbilt University Medical Center, spoke with CancerNetwork® about the benefits of a conference like the American Association for Cancer Research (AACR) Annual Meeting 2021, and how the collaborative network of thought leaders presents ample opportunity to move the field forward.

Transcription:

What I think the AACR Annual Meeting does is bring together experts from a multitude of fields across the globe to really aim towards one specific goal of understanding cancer and reducing the burden of cancer worldwide. I think that’s a really unique opportunity because these different presentations, mine as well as other posters, other sessions, really afford the opportunity to forge connections and collaborations that you may not have had within your inner network. [Connecting] folks of different expertise may yield just fantastic team science and translational work to answer important questions like these in early-onset colorectal cancer. I’m most excited for that, in addition to presenting these findings, the provocative discussion that will be held both with these results and how we as a field can move forward to really make that precision medicine impact for individual patients overall. From basic science to population science, you’re really bringing together a [group] of experts to really build upon what we already know and go in ways that we may not have thought of individually.

Reference:

Holowatyj AN, Wen W, Gibbs T, et al. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases. Presented at: AACR Annual Meeting 2021. Virtual. Abstract 101.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content